ERBB2 and breast cancer: Breast cancer is one of the first solid malignancies in which a defined genomic event with clear clinical and pathological implications, human epidermal growth factor receptor 2 (HER2) amplification, was found and for which a targeted agent that clearly modifies the natural history of the disease was made readily available [3].